FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Thompson Kweli 2. Date of Event Requiring Statement (Month/Day/Year) 06/18/2026 3. Issuer Name and Ticker or Trading Symbol Medtronic plc [MDT] (Last) (First) (Middle) 710 MEDTRONIC PARKWAY 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP & President, Neuroscience 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) MINNEAPOLIS, MN 55432 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Shares 30,017.737(1) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	(2)	(2)	Ordinary Shares	3,252.987(3)	(4)	D
Performance Share Units	(5)	(5)	Ordinary Shares	9,911.187(6)	(4)	D
Performance Share Units	(7)	(7)	Ordinary Shares	9,178.809(8)	(4)	D
Stock Option (Right to Buy)	08/01/2017(9)	08/01/2026	Ordinary Shares	1,704	$88.06	D
Stock Option (Right to Buy)	01/30/2018(9)	01/30/2027	Ordinary Shares	1,608	$74.67	D
Stock Option (Right to Buy)	07/31/2018(9)	07/31/2027	Ordinary Shares	4,407	$83.97	D
Stock Option (Right to Buy)	07/30/2019(9)	07/30/2028	Ordinary Shares	6,271	$89.08	D
Stock Option (Right to Buy)	07/29/2020(9)	07/29/2029	Ordinary Shares	1,615	$103.26	D
Stock Option (Right to Buy)	08/03/2021(9)	08/03/2030	Ordinary Shares	10,181	$97.33	D
Stock Option (Right to Buy)	08/02/2022(9)	08/02/2031	Ordinary Shares	6,358	$131.26	D
Stock Option (Right to Buy)	08/01/2023(9)	08/01/2032	Ordinary Shares	26,890	$93.08	D
Stock Option (Right to Buy)	07/31/2024(9)	07/31/2033	Ordinary Shares	25,408	$87.76	D
Stock Option (Right to Buy)	07/29/2025(9)	07/29/2034	Ordinary Shares	1,540	$80	D
Stock Option (Right to Buy)	07/28/2026(9)	07/28/2035	Ordinary Shares	22,363	$91.97	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Thompson Kweli 710 MEDTRONIC PARKWAY MINNEAPOLIS, MN 55432			EVP & President, Neuroscience

Signatures

/s/ Patricia Walesiewicz, attorney-in-fact		06/26/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes 6,549 performance stock units that vested on April 24, 2026; 1,822 restricted stock units that vested on December 6, 2025; 3,742.990 restricted stock units that vest on July 31, 2026; 3,402.644 restricted stock units that vest on December 6, 2026; 9,911.187 restricted stock units that vest on July 29, 2027; 4,589.916 restricted stock units that vest on July 28, 2028.
(2)	The performance share units ("PSUs") vest on December 6, 2026.
(3)	The number of shares to be issued in connection with the PSUs reported reflects the amount earned based on achievement of applicable performance criteria. The award remains subject to time-based vesting.
(4)	Each PSU represents a contingent right to receive one share of Medtronic common stock.
(5)	The PSUs vest on April 30, 2027.
(6)	The number of shares to be issued in connection with PSUs will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 9,911.187 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares.
(7)	The PSUs vest on April 28, 2028.
(8)	The number of shares to be issued in connection with the PSUs will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 9,178.809 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares.
(9)	These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.